A Phase I/II Study of (177Lu)-Lilotomab (Betalutin®) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma.

Trial Profile

A Phase I/II Study of (177Lu)-Lilotomab (Betalutin®) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; MALT lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man
  • Acronyms LYMRIT37-01
  • Sponsors Nordic Nanovector
  • Most Recent Events

    • 13 Sep 2017 Planned number of patients changed from 70 to 77.
    • 13 Sep 2017 Planned primary completion date changed from 1 May 2017 to 1 Oct 2017.
    • 25 Jun 2017 Results of a pharmacokinetic sub-study (n=22), presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top